+Compare
MRSN
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
153.04M

MRSN Mersana Therapeutics Forecast, Technical & Fundamental Analysis

a developer of antibody drug conjugates to improve patient outcomes in multiple oncology indications

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for MRSN with price predictions
08:00 PM EDT Sep 19, 2023

MRSN saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for MRSN moved out of overbought territory on September 20, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 51 similar instances where the indicator exited the overbought zone. In of the 51 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRSN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MRSN broke above its upper Bollinger Band on September 13, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MRSN's RSI Indicator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on September 06, 2023. You may want to consider a long position or call options on MRSN as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MRSN advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.704) is normal, around the industry mean (22.685). P/E Ratio (0.000) is within average values for comparable stocks, (131.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.923). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (3.460) is also within normal values, averaging (316.663).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRSN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRSN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 402 to 424.75B. NVO holds the highest valuation in this group at 424.75B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was 26%, and the average quarterly price growth was 31%. APLT experienced the highest price growth at 58%, while SEEL experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was 29% and the average quarterly volume growth was 43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 63
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

MRSN is expected to report earnings to fall 24.02% to -35 cents per share on November 07

Mersana Therapeutics MRSN Stock Earnings Reports
Q3'23
Est.
$-0.36
Q2'23
Missed
by $0.03
Q1'23
Missed
by $0.09
Q4'22
Beat
by $0.05
Q3'22
Missed
by $0.61
The last earnings report on August 08 showed earnings per share of -46 cents, missing the estimate of -43 cents. With 1.32M shares outstanding, the current market capitalization sits at 153.04M.
A.I. Advisor
published General Information

General Information

a developer of antibody drug conjugates to improve patient outcomes in multiple oncology indications

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
840 Memorial Drive
Phone
+1 617 498-0020
Employees
228
Web
https://www.mersana.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSJIX13.16N/A
N/A
JHancock Small Cap Growth I
WLVIX6.23-0.08
-1.27%
Westwood Total Return Inst
JHISX9.30-0.15
-1.59%
Janus Henderson VIT Global Sust Eq Ins
OMSCX18.47-0.32
-1.70%
Invesco Main Street All Cap C
DEMRX17.70-0.34
-1.88%
Delaware Emerging Markets R

MRSN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRSN has been loosely correlated with MDGL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MRSN jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRSN
1D Price
Change %
MRSN100%
-0.79%
MDGL - MRSN
45%
Loosely correlated
-1.18%
ZNTL - MRSN
40%
Loosely correlated
-1.69%
AVTX - MRSN
38%
Loosely correlated
-7.99%
ARRY - MRSN
36%
Loosely correlated
-1.39%
EDIT - MRSN
34%
Loosely correlated
+0.75%
More

Groups containing MRSN

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRSN
1D Price
Change %
MRSN100%
-0.79%
cancer
(undefined stocks)
23%
Poorly correlated
-1.15%
antibody
(undefined stocks)
18%
Poorly correlated
+0.15%
biotechnology
(undefined stocks)
17%
Poorly correlated
-1.72%
drugs
(undefined stocks)
17%
Poorly correlated
-1.74%